Arrowhead has dosed the first participant in the Phase III YOSEMITE trial of zodasiran, under development for treating HoFH.

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for NMOSD.